Indication

As monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Medicine details

Medicine name:
trifluridine/tipiracil (Lonsurf)
SMC ID:
SMC2329
Pharmaceutical company
Servier Laboratories Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
Q2 2021
SMC meeting date:
Q2 2021
Patient group submission deadline:
01 March 2021